Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.60 |
| ▸ | CTSS | P25774 | 11/20 | 0.54 |
| ▸ | CTSK | P43235 | 10/20 | 0.53 |
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241676 | 0.90 | SYK (0.61) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL606625 | 0.88 | SYK (0.65) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL1022494 | 0.88 | SYK (0.65) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL17841824 | 0.88 | SYK (0.65) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL9227553 | 0.88 | SYK (0.62) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL14842312 | 0.87 | SYK (0.64) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL6231600 | 0.87 | SYK (0.64) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL20297671 | 0.87 | SYK (0.64) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL18340847 | 0.87 | SYK (0.64) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL30967604 | 0.87 | SYK (0.58) | SYKCTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338975-B2 | Lactams as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20040186143-A1 | Lactams as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| WO-2004071449-A2 | LACTAMS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186143-A1 | Lactams as modulators of chemokine receptor activity | CCL11, CCR1, CXCR1 | SYK 3499/4885CTSS 493/4885CTSK 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.